11 results about "Post infection" patented technology

The invention relates to the field of veterinary protozoology and methods for producing antigens, particularly for the diagnosis of Surra Su-Auru in animals. The objective of the invention is to develop a method for producing a highly sensitive trypanosomal antigen for the serological diagnosis of Surra (Su-Auru) in animals. The problem is solved by the fact that the method for obtaining trypanosome antigen for serological diagnostics of Surra (Su-Auru) in animals involves infecting rabbits intratesticularly with live trypanosomes of the T species. evansi, removal of the spleen 2-3 days after infection, total bleeding 8-10 days after splenectomy (parasitemia -80-90%), blood is collected in a wide vessel with 2% sodium citrate in physiological solution with constant stirring with a glass rod, at the rate of 1 part blood to 2 parts solution, settling of citrated blood in the refrigerator for 18-24 hours, centrifugation and separation of the middle layer from the sediment from the supernatant, 2-3 times washing of trypanosomes in physiological solution, at 3000-5000 rpm, for 10 minutes each, disintegration of the centrifugate by ultrasound at a frequency of 22 kHz, power of 60 W / cm2 for 8-12 minutes, followed by centrifugation of the disintegrate at 8000-10000 rpm for 20-30 minutes and collection of sediment (endoantigen), treatment of the supernatant with TCA, collection of the precipitated sediment (exoantigen), batches of sediment are mixed 10:1. The technical result provided by the utility model is expressed in the development of a method for obtaining a highly sensitive trypanosomal antigen for the serological diagnosis of Surra (Su-Auru) in animals.

Embodiments of therapeutic protocols to treat Post-Acute Sequelae SARS-COV-2 infection (“PASC”), a.k.a. “long Covid,” are described. The PASC treatment protocols focus on a moderating a hyperimmune response; destroying and removing the SARS COV-2 spike protein from the gut and body, detoxifying the body and the brain; replenishing key nutrients; mitigating depression and anxiety; and a regimen of physical and mental exercises. A standard six-week protocol and a shorter, three-week protocol are disclosed for those with a milder form of PASC are disclosed.

The application provides use of indole-3-propionic acid (IPA) in anti-herpes virus and a medicine and a feed additive containing the indole-3-propionic acid, and belongs to the technical field of biological medicine. The application provides application of the IPA in preparation of an antiviral agent for herpes virus, and after intervention of the IPA, the survival rate of infected mice can be obviously improved. Furthermore, after intervention of the IPA, the index of the parenchyma organs of the mice is obviously lower than that of a positive infection group; the level of inflammatory factors in each organ in the later infection stage is obviously improved, and the intestinal barrier is obviously improved; the intervention of the IPA can also obviously reduce the transcription level of PRV related genes. The IPA has the function of inhibiting pseudorabies virus replication, and can be used for preparation of a medicine for preventing and / or treating diseases caused by herpes virus infection or a corresponding feed additive.

The application discloses a kind of intelligent integrated ventricular drainage device and control method based on multi-source data fusion, the device is monitored in real time by micro bioelectrochemical impedance sensor electrochemical characteristics of drainage fluid, and fuses clinical physiological indicators, constructs 7-dimensional infection risk assessment vector;Infection super-early warning is realized using random forest machine learning algorithm, average early warning time is 8 hours, accuracy is 86.8%;Through adaptive PID control, intracranial pressure is finely adjusted, average control error is ≤2 mmHg, error <2mmHg time ratio reaches 94.5%;Integrating honeycomb micropore design and vibration anti-blocking module, effectively prevent drainage tube blockage, simulation research shows that the system can increase infection prevention rate to 70%, hospitalization time is reduced by 3.2 days, bed rotation rate is increased by 47%, realizes the innovation of clinical management mode from "infection treatment" to "infection prevention", and is assisted by anti-blocking device, pressure regulating device and the like structure, combination improves the overall drainage effect.

A nanosystem and methods of treating, including prophylactically, coronavirus infections, such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by administering such nanosystem to a patient is presented. The nanosystem may be comprised of a single or a combination of therapeutic agents, optionally encapsulated in a nanoparticle having a targeting moiety directed to the particular coronavirus. For CoV-2 infections, at least one therapeutic agent, such as the dual DPP4 / ACE2 inhibitor sitagliptin, may optionally be encapsulated within a nanoparticle having a fatty acid such as linoleic acid, as the targeting moiety. Administration can occur intranasally prior to infection for prophylactic treatment or post-infection for treatment of the viral infection.

This application discloses a method for monitoring and assessing the replication of Wenzhou-related virus (WZRV) infection based on mouse lung and / or kidney organoids. The method includes: obtaining lung and / or kidney organoids from SD rats; infecting the organoids with WZRV; culturing the infected organoids; and collecting samples at different time points after infection for viral replication and tissue tropism analysis. This application establishes a standardized lung / kidney organoid model from SD rats and, combined with multi-dimensional detection methods such as RT-qPCR nucleic acid quantification, infectivity titer determination, immunofluorescence co-localization, and transmission electron microscopy, can systematically assess viral replication kinetics, tissue / cell tropism, and morphogenesis characteristics. This application constructs a reproducible and comparable standardized assessment system that realistically reflects the replication behavior and target cell preference of WZRV under near-physiological conditions, providing a reliable in vitro platform for viral pathogenesis research and antiviral drug screening.

The application discloses application of a small-molecule compound HAMNO in resisting African swine fever virus infection and belongs to the technical field of biological medicines. The application finds that the small-molecule compound HAMNO has a significant inhibitory effect on the replication of African swine fever virus, can significantly reduce the titer of African swine fever virus in host cells, and the inhibitory effect presents an obvious dose-dependent relationship. In addition, the application proves that the small-molecule compound HAMNO can produce a significant inhibitory effect on the virus whether used before or after virus infection, indicating that the compound has a dual effect of preventing and treating African swine fever virus infection and is an excellent raw material for developing antiviral drugs. The application provides a new drug raw material for African swine fever virus infection and a new prevention and treatment scheme for resisting African swine fever virus infection.

This invention relates to the field of pathogen infection detection technology, specifically a method for visually tracking human bronchial organoids infected with Mycoplasma pneumoniae. It includes the following steps: (1) Constructing human bronchial organoids: culturing mature human bronchial organoids with cavities, the organoids comprising ciliated cells, basal cells, goblet cells, and Club cells, having a polarized three-dimensional structure with the apex facing outwards; (2) Mycoplasma pneumoniae culture and fluorescent labeling: Mycoplasma pneumoniae is amplified and cultured in MP complete medium, and then fluorescently labeled using CellTrace far-infrared cell staining solution; (3) Co-culture for infection: Mycoplasma pneumoniae fluorescently labeled in step (2) is co-cultured with the human bronchial organoids from step (1) for infection; (4) Live cell dynamic fluorescence tracking: Non-invasive in situ continuous imaging is performed on the human bronchial organoids infected by MP in step (3). This invention can achieve non-invasive dynamic tracking of the entire process of MP infection.

The application discloses application of icariside II in the technical field of traditional Chinese medicine pharmacy in preparation of a medicine for resisting coxsackieviruses group B3 (CVB3). The present application takes VERO (African green monkey kidney) and Hela (HeLa) cells infected by CVB3 as research models, detects the influence of icariside II on cell cytopathic effect (CPE) after infection by CVB3, on virus titer in supernatant, and on transcription level of CVB3 mRNA, and the results show that icariside II has obvious anti-CVB3 effect and can be used for preparation of a medicine for resisting CVB3.